Centre de Référence Maladies Rares

U1035 INSERM

Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC)

FR: Biologie Fondamentale Appliquée à la Médecine

U1035Display navigation projects FR / EN

Dermatology team
Project 2.4

Physiopathology of pigmentation and tissue engineering

keywords: melanocytes, vitiligo, scleroderma, reconstructed epidermis, metabolism

Description:

Melanin is the pigment produced by melanocytes that after transfer to surrounding keratinocytes ensures specifically the protection against the harmful effects of ultraviolet and the color of the skin. The skin color and ability to tan conventionally determine six phototypes, going from light to dark. These skin types are not related to a difference in the melanocyte numbers but to their ability to produce pheomelanin (yellow-orange) or eumelanin (brown-black) that is transferred according to its type in pheomelanosomes or eumelanosomes to keratinocytes. The diseases that are associated with local or generalized skin color alteration are generally used as a model for studying the regulation of melanogenesis. To study the physiology of pigmentation, we use reconstructed epidermis, a model that has been qualified based on its capacities to respond to UV and to reproduce the epidermal melanin unit. This model allows us to study the role of epidermal and dermal cells on pigmentation, modeling different pigmentary disorders (using patient cells or genetically modified cells), identifying the key factors (CCN3 in vitiligo), and to evaluate the effect of stimuli supposed to be involved in the etiology of these pathologies. Our main modeled diseases are vitiligo (depigmentation associated with progressive loss of melanocytes), Cole disease (hypo or hyyer pigmentation related to ENNP-1 mutation), scleroderma (fibrosis related to an overproduction of collagen by fibroblasts associated with hypo- and hyper-pigmentation disorders), senile or solar lentigo (hyperpigmentation related to age or sun exposure). We are currently studying the role of oxidative and energy metabolism on physiopathology of these pigmentary disorders and the influence of fibroblasts on pigmentation.

Related publications:

  • Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: analysis of a cohort of 239 patients. Leroy V, Henrot P, Barnetche T, Cario-André M, Darrigade AS, Manicki P, Doutre MS, Lazaro E, Constans J, Barcat D, Vernhes JP, Richez C, Taieb A, Truchetet ME, Seneschal J ; FHU ACRONIM. J Am Acad Dermatol. (2018-08-06) PMID: 30092330
  • Epidermal melanocytes in segmental vitiligo show altered expression of E-cadherin, but not P-cadherin. Grill C, Benzekri L, Rubod A, Aktary Z, Ezzedine K, Taïeb A, Gauthier Y, Larue L, Delmas V. Br J Dermatol. (2018-05) PMID: 29341072
  • Skin equivalents: skin from reconstructions as models to study skin development and diseases. Ali N, Hosseini M, Vainio S, Taïeb A, Cario-André M, Rezvani HR. Br J Dermatol. (2015-08) 173(2):391-403
  • Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. Wagner RY, Luciani F, Cario-André M, Rubod A, Petit V, Benzekri L, Ezzedine K, Lepreux S, Steingrimsson E, Taieb A, Gauthier Y, Larue L, Delmas V. J Invest Dermatol. (2015-07) 135(7):1810-9
  • Vitiligo. Picardo M, Dell’Anna M.L, Ezzedine K, Hamzavi I, Harris JE, Parsad D, Taieb A. Nat Rev Dis Primers. (2015) doi:10.1038/nrdp.2015.11
  • Factors secreted by irradiated aged fibroblasts induce solar lentigo in pigmented reconstructed epidermis. Salducci M, André N, Guéré C, Martin M, Fitoussi R, Vié K, Cario-André M. Pigment Cell Melanoma Res. (2014-05) 27(3):502-4
  • Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin. Ricard AS, Pain C, Daubos A, Ezzedine K, Lamrissi-Garcia I, Bibeyran A, Guyonnet-Dupérat V, Taieb A, Cario-André M. Exp Dermatol. (2012-06) 21(6):411-6

Back to team's projects

INSERM U1035! - University of Bordeaux
Work
146 rue Léo Saignat - PE building south zone, 4th floor
33000 Bordeaux
Aquitaine
France
Work +33 557 57 13 73/74
sarah.lesjean@inserm.fr